Patents by Inventor Iram Khan

Iram Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC GENOME EDITING IN WISKOTT-ALDRICH SYNDROME AND X-LINKED THROMBOCYTOPENIA
    Publication number: 20240141389
    Abstract: Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
    Type: Application
    Filed: April 5, 2023
    Publication date: May 2, 2024
    Inventors: David J. Rawlings, Iram Khan
  • Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
    Patent number: 11939594
    Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 26, 2024
    Assignee: Seattle Children's Hospital
    Inventors: David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung, Andrew M. Scharenberg
  • Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
    Patent number: 11643671
    Abstract: Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 9, 2023
    Assignee: Seattle Children's Hospital
    Inventors: David J. Rawlings, Iram Khan
  • THERAPEUTIC GENOME EDITING IN WISKOTT-ALDRICH SYNDROME AND X-LINKED THROMBOCYTOPENIA
    Publication number: 20200325494
    Abstract: Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
    Type: Application
    Filed: April 19, 2018
    Publication date: October 15, 2020
    Inventors: David J. Rawlings, Iram Khan
  • ENGRAFTABLE CELL-BASED IMMUNOTHERAPY FOR LONG-TERM DELIVERY OF THERAPEUTIC PROTEINS
    Publication number: 20180282692
    Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.
    Type: Application
    Filed: March 14, 2018
    Publication date: October 4, 2018
    Inventors: David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung